Effect and safety of NN9535 in weight management (NN9536-4382)
Phase 3
Completed
- Conditions
- Overweight or obesity
- Registration Number
- JPRN-jRCT2080224531
- Lead Sponsor
- ovo Nordisk Pharma Ltd.
- Brief Summary
Semaglutide 2.4 mg and semaglutide 1.7 mg were superior to placebo with respect to weight loss (-13.19% vs-9.65% vs -2.12%; ETD Sema 2.4 mg:-11.06% [-12.88; -9.24]95% CI; ETD Sema 1.7 mg: -7.52% [-9.62; -5.43]95% CI), including 5, 10 and 15% weight loss responders and waist circumference "-Semaglutide 2.4 mg and semaglutide 1.7 mg were overall well tolerated and the safety and tolerability profiles were consistent with the GLP-1 RA class in general
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 401
Inclusion Criteria
BMI >= 27.0 kg/m2 with >= 2 weight related comorbidities or BMI >= 35.0 kg/m2 with >= 1 weight related comorbidity
Exclusion Criteria
Severe heart failure, History of pancreatitis, Severe psychological disorder, other
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method